management and epidemiology of AF have been changing rapidly. We need a contemporary, cross-sectional, and international survey of different types of AF to describe their risk profiles and management strategy and to provide further insight of patients with AF in our routine daily practice.
The Real-life global survey evaluating patients with atrial fibrillation (RealiseAF) survey was established to describe patient characteristics, cardiovascular risk, types of AF, symptoms, medical history, and management strategies in real-life practice. 9
Methods Design
As previously published, 9 RealiseAF was a cross-sectional observational survey of >10 000 patients with AF seen at >800 sites in 26 countries from October 2009 to May 2010. Participating countries were Algeria, Azerbaijan, Belgium, Bulgaria, Czech Republic, Egypt, Germany, Hungary, India, Ireland, Italy, Lebanon, Lithuania, Mexico, Morocco, Portugal, Russia, Slovakia, Spain, Sweden, Switzerland, Taiwan, Tunisia, Turkey, Ukraine, and Venezuela.
Patients
Patients with a history of AF (treated or not, and whatever the rhythm was at the time of inclusion), with at least 1 AF episode documented by standard ECG or by Holter-ECG in the previous 12 months, or documented current AF, who provided written, informed consent, were enrolled. Exclusion criteria were limited to mental disability (such as dementia or significant cognitive disorders), inability to provide written, informed consent, postoperative AF within 3 months of cardiac surgery, and participation in clinical trials investigating AF or antithrombotics during the previous month.
Selection of Investigators
Participating physicians were randomly selected from a global list of cardiologists and internists (office-and hospital-based) in each country in 2009 to 2010. The ratio of cardiologists to internists was predetermined to reflect the practice in each country so that unbiased recruitment could be achieved. The list and ratio were validated by national coordinators. The maximum duration of enrolment per center was 6 weeks to maximize recruitment of consecutive patients. Each investigator was asked to recruit a minimum of 10 patients and a maximum of 30.
Objectives
The primary objectives of this analysis were to describe the clinical characteristics, risk factors and comorbidities, management strategy, and control of AF in patients with paroxysmal, persistent, or permanent AF. Control of AF was defined as either being in sinus rhythm on an ECG or being in AF with a resting ventricular rate ≤80 beats per minute on resting ECG at the time of the visit. A post hoc sensitivity analysis was also performed to evaluate the proportion of patients in AF with a ventricular rate ≥110 beats per minute. 10
Statistical Analysis
The details of the determination of sample size have been described previously. 9 Population characteristics were summarized as mean and SD for continuous variables and as count and percentages for qualitative variables. Comparisons between subgroups were made using the χ 2 test, Fisher exact test for nominal variables, trend test for ordinal variables, or ANOVA for quantitative variables. Analyses were performed using the SAS statistical software, version 9.1 (SAS Institute, Cary, NC).
Results
RealiseAF included 10 546 patients from 831 sites in 26 countries on 4 continents. Participating physicians were 83.1% cardiologists, 7.8% internists, and 9.1% physicians who defined themselves as both a cardiologist and an internist. Excluding 23 ineligible patients, 675 patients who had a first episode of AF, and 32 patients with missing data on the type of AF, there were 9816 patients eligible for the current analysis, of whom 2606 (26.5%) had paroxysmal, 2341 (23.8%) persistent, and 4869 (49.6%) permanent AF. 2 Baseline characteristics are shown in Table 1 . Mean age was highest in patients with permanent AF, who also had the longest duration of AF since diagnosis. There were more men than women in all groups ( Table 1 ).
Cardiovascular Risk Factors and Comorbidities
Patients with AF had multiple cardiovascular risk factors, as shown in Table 2 . Hypertension was the most common, followed by physical inactivity and dyslipidemia. Approximately a fifth of the patients had diabetes mellitus across the various AF subsets. Although hypertension and dyslipidemia were slightly less frequent in patients with permanent AF than in those with paroxysmal AF, patients with permanent AF had more comorbidities ( Table 3 ). The prevalence of comorbidities, particularly heart failure, coronary artery disease, cerebrovascular disease, valvular heart disease, and chronic pulmonary disease, increased in a stepwise fashion from paroxysmal to persistent to permanent AF. Similarly, the prevalence of lone AF decreased from paroxysmal to persistent and permanent AF.
Distribution of CHADS 2 Score
The distribution of CHADS 2 scores across the various types of AF is shown in Table 4 . The mean CHADS 2 score increased, as did the proportion of patients with a CHADS 2 score ≥2, as AF progressed from paroxysmal to permanent. Among patients meeting criteria for anticoagulation (CHADS 2 ≥2), the percentage of patients actually receiving oral anticoagulant (OAC) was 37.7%, 54.4%, and 59.0% for paroxysmal, persistent, and permanent AF, respectively (P<0.0001). Figure 1 shows use of antiarrhythmic drugs (AADs) in different types of AF. More than 80% of patients received at least 1 AAD. Class Ia drugs were rarely used. Class Ic drugs, such as propafenone, flecainide, and sotalol, were more commonly used in patients with paroxysmal AF. Amiodarone was more frequently used for persistent AF. Interestingly, 12% of patients with permanent AF received amiodarone, presumably as a rate-control agent. Class II and IV drugs, as well as cardiac glycosides, were more commonly prescribed in patients with permanent AF as rate-control agents. Figure 2 shows the distribution of the use of medications across all groups. The use of diuretics, nitrates, angiotensinconverting enzyme inhibitors, and antidiabetic drugs were more common as patients progressed from paroxysmal to persistent and permanent AF.
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Symptoms
Despite the fact that almost 90% of patients had received at least 1 AAD during the previous 7 days, symptom relief was poor; ≈60% of patients across all groups had at least 1 symptom during the last week before the visit ( Table 5 ). Palpitations were less common in patients with permanent AF, whereas dyspnea and fatigue were less prevalent in patients with paroxysmal AF. The vast majority of patients had European Heart Rhythm Association (EHRA) symptom scores from II to IV (two thirds of patients with paroxysmal AF, three quarters of patients with persistent and permanent AF).
Hospitalizations
Up to ≈30% of patients had experienced at least 1 admission because of a cardiovascular event in the past 12 months (Figure 3 ). Acute decompensation of heart failure was the leading cause in persistent and permanent AF. Stroke rates were higher for patients with persistent than paroxysmal AF and highest in patients with permanent AF. In turn, arrhythmic or proarrhythmic events were most frequent in patients with paroxysmal AF. Up to 12.3% of patients with paroxysmal AF had at least one such event.
Control of AF
The percentage of patients with uncontrolled AF (defined as being in AF with a ventricular rate >80 beats per minute) was 19.8%, 40.7%, and 49.8% for paroxysmal, persistent, and permanent AF, respectively (P<0.0001) (Figure 4) . When a ventricular rate ≥110 beats per minute was used, the percentages were 10.1%, 15.2%, and 10.8%, respectively (P<0.0001).
Management Strategies
Management strategies before and after the visit are shown in Table 6 . Rhythm-control strategy was applied in >50% of patients with paroxysmal or persistent AF before the visit. Interestingly, there were still 9% of patients with permanent AF in whom the investigators settled on a rhythm-control strategy. After the study visit, there was a decrease in the proportion of patients in whom no clear strategy was selected (neither rhythm-control nor rate-control strategy). More patients with paroxysmal or persistent AF experienced changes in their management strategies (17.7% and 24.4%, respectively) than patients with permanent AF (8.5%).
Discussion
The RealiseAF survey provides a unique opportunity to examine the risk profile and management of different types of AF in daily practice on an international basis. We found that as AF progressed from paroxysmal to persistent and permanent forms, there was an increase in the prevalence of comorbidities, the risk of thromboembolism, and acute decompensation of heart failure. Patients became more frequently symptomatic, and AF was less frequently controlled (at least when AF control was defined with a stringent heart rate <80 beats per minute).
Studies of paroxysmal or persistent AF are common. 7 However, studies of the full spectrum of AF, including permanent AF, are more scarce. 5 The Euro Heart Survey on AF described AF management for different types of AF in European countries, in which the national coordinator from each country supplied a list of centers that would be suitable to participate in the survey. 5 The authors noted that they may have had an overrepresentation of highly specialized and AF-interested centers. 5 In contrast, RealiseAF was an international survey comprising data from 26 countries across 4 continents, and investigators were randomly selected, suggesting it represents a valid global contemporary survey of full-spectrum AF in common clinical practice.
RealiseAF did not enroll patients from Canada or the United States, but its results are highly consistent with those from a large North American cross-sectional study describing prevalence and risk factors of AF. 6 The prevalence of comorbidities, such as heart failure (29.2%), coronary artery disease (34.6%), and diabetes mellitus (17.1%), in AF patients in their study, which also enrolled black patients, was high and similar to those reported in RealiseAF.
Patient Characteristics, Risk Factors, and Comorbidities
Generally, patients enrolled in clinical trials are highly selected and are at lower risk of adverse outcomes than patients from routine practice, which limits the external validity of clinical trials. Interestingly, the prevalence of comorbidites in RealiseAF was quite similar to that observed in recent large clinical trials. In the ATHENA (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter) trial, which enrolled patients with paroxysmal or persistent AF aged at least 70 years, 11 there were 21.1% of patients with heart failure New York Heart Association II or III. In RealiseAF, the percentages of patients with heart failure New York Heart Association II to IV were 27.3% for patients with paroxysmal AF and 38.0% for patients with persistent AF. Clearly, RealiseAF had more patients with moderate to severe heart failure than the ATHENA trial. Again, 30.4% of patients in ATHENA had coronary artery disease, whereas in RealiseAF, 30.0% of patients with paroxysmal AF and 32.9% with persistent AF had coronary artery disease. In the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial, 8 there were only 23.1% of patients with heart failure and 26.1% of patients with coronary artery disease, which were less than in RealiseAF. Our findings confirm the high cardiovascular risk of AF patients seen in daily practice. As AF progressed from paroxysmal to persistent and permanent forms, there was a concomitant increase in the cardiovascular risk profile. The risk of patients in permanent AF is of particular concern because 84.8% of patients had at least 1 comorbidity.
CHADS 2 Score
The CHADS 2 scores were higher than previously reported in patients with AF in real-life practice. 3, 4 The percentage of patients with CHADS 2 scores ≥2, that is, who had clear-cut indications for OAC therapy, was 51.0%, 56.7%, and 67.3% among patients with paroxysmal, persistent, and permanent AF, respectively. The distribution of CHADS 2 scores in patients with permanent AF in the RealiseAF survey was quite similar to that seen in recent antithrombotic trials in AF. 12, 13 
Symptoms
About 60% of patients with AF complained of symptoms. Interestingly, palpitation was not necessarily the most common symptom. In patients with persistent and permanent AF, dyspnea and fatigue were more frequently reported. When an EHRA symptom score ≥II was considered, patients with paroxysmal AF were less symptomatic than patients with permanent AF. Because symptoms predicted an adverse outcome independent of associated cardiovascular disease in a recent study of AF, 7 we may need to reconsider the clinical significance of symptoms associated with AF, beyond their relevance to quality of life. On the other hand, AADs were not effective in ameliorating symptoms: almost 90% of patients in RealiseAF received at least 1 AAD, yet prevalence of symptoms was high.
Management Strategy and Control of AF
Although a rhythm-control strategy has not been shown to be superior to a rate-control strategy in reducing cardiovascular events in patients with nonpermanent AF, it is still more commonly used. 5, 15, 16 This was also the case in RealiseAF. We also found that there was a change in strategy among 17.7% of patients with paroxysmal AF and 24.4% of patients with persistent AF, mainly because of an increase in the rhythmcontrol strategy and a decrease in the proportion of patients in whom no clear strategy was declared.
The RACE II trial [RAte Control Efficacy in permanent atrial fibrillation] suggested noninferiority of lenient compared with strict rate control. 10 However, RealiseAF was designed before publication of these results. 7, 17 Therefore, control of AF in the RealiseAF survey was defined as either being in sinus rhythm or being in AF with a resting ventricular rate ≤80 beats per minute. Although there were only 10.8% of permanent AF patients who had uncontrolled AF (a ventricular rate ≥110 beats per minute) based on a lenient-control strategy, 77.1% of them were symptomatic according to their EHRA score.
A hierarchical model would be the best way to control for random variation across sites and countries. Any association may be confounded by factors, including but not limited to differences in diagnosis, access to cases, and ethnicity. Most of the data presented in this article were descriptive in nature, without inferring associations. A single-level model, as used in the present study, may be sufficient.
Limitations
The present report should be interpreted cautiously, given its observational and cross-sectional nature. Despite the wide geographic scope of this study, it does not include Central Africa or the United States and Canada. There are likely major differences in patient characteristics and management in these regions. However, RealiseAF has unprecedented geographic relevance by including many developing low-and middleincome countries.
Conclusions
RealiseAF is an international survey of different types of AF in daily practice and provides a snapshot of real-world data regarding the risk level and AF management strategy on a global basis. About half of all patients had permanent AF, whereas paroxysmal and persistent AF equated a quarter each. Risk factors and comorbidities were common and similar to those in clinical trials. The prevalence of moderate to severe heart failure, coronary artery disease, diabetes mellitus, and cerebrovascular disease increased from paroxysmal to permanent AF. More than half of all patients with AF qualified for the use of OACs, but OACs were inadequately used. AADs were not effective in reducing symptoms or in maintaining sinus rhythm. The RealiseAF survey disclosed high cardiovascular risks and an unmet need in our daily practice in patients with AF, especially the permanent form. AF indicates atrial fibrillation.
